BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36915123)

  • 1. Narsoplimab for severe transplant-associated thrombotic microangiopathy.
    Pandrowala A; Ganatra P; Krishnan VP; Sharma AN; Chavan S; Bodhanwala M; Agarwal B; Hiwarkar P
    Thromb J; 2023 Mar; 21(1):26. PubMed ID: 36915123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
    Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
    Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.
    Elhadad S; Redmond D; Huang J; Tan A; Laurence J
    Clin Exp Immunol; 2023 Jul; 213(2):252-264. PubMed ID: 37191586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
    Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
    Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.
    Castelli M; Micò MC; Grassi A; Algarotti A; Lussana F; Finazzi MC; Rambaldi B; Pavoni C; Rizzuto G; Tebaldi P; Vendemini F; Verna M; Bonanomi S; Biondi A; Balduzzi A; Rambaldi A; Gotti G
    Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38773280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow transplant-associated thrombotic microangiopathy without peripheral blood schistocytes: a case report and review of the literature.
    Wirtschafter E; VanBeek C; Linhares Y
    Exp Hematol Oncol; 2018; 7():14. PubMed ID: 29977661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
    Khaled SK; Claes K; Goh YT; Kwong YL; Leung N; Mendrek W; Nakamura R; Sathar J; Ng E; Nangia N; Whitaker S; Rambaldi A;
    J Clin Oncol; 2022 Aug; 40(22):2447-2457. PubMed ID: 35439028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.
    Dudler T; Yaseen S; Cummings WJ
    Front Immunol; 2023; 14():1297352. PubMed ID: 38022610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic Microangiopathy With Granulomatosis Interstitial Nephritis in an Allogenic Bone Marrow Transplant Patient: A Case Report and Review of the Literature.
    Mirza AS; Verma S; Fu L; Bassil C
    J Hematol; 2017 Sep; 6(2-3):52-58. PubMed ID: 32300393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
    Elhadad S; Chapin J; Copertino D; Van Besien K; Ahamed J; Laurence J
    Clin Exp Immunol; 2021 Jan; 203(1):96-104. PubMed ID: 32681658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.
    Ardissino G; Capone V; Tedeschi S; Porcaro L; Cugno M
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Successful Treatment With Anti-C5 Monoclonal Antibody in a Japanese Adolescent Who Developed Thrombotic Microangiopathy After Autologous Bone Marrow Transplantation for Malignant Lymphoma.
    Shimizu S; Morohashi T; Kanezawa K; Yagasaki H; Takahashi S; Morioka I
    Front Pediatr; 2022; 10():908183. PubMed ID: 35859949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.
    Lazana I
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transplant-Associated Thrombotic Microangiopathy in Pediatric Hematopoietic Cell Transplant Recipients: A Practical Approach to Diagnosis and Management.
    Dvorak CC; Higham C; Shimano KA
    Front Pediatr; 2019; 7():133. PubMed ID: 31024873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
    Higham CS; Shimano KA; Melton A; Kharbanda S; Chu J; Dara J; Winestone LE; Hermiston ML; Huang JN; Dvorak CC
    Pediatr Blood Cancer; 2022 May; 69(5):e29641. PubMed ID: 35253361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients.
    Jodele S; Sabulski A
    Expert Rev Hematol; 2021 Aug; 14(8):751-763. PubMed ID: 34301169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report.
    Nunius C; Büttner-Herold M; Bertz S; Schiffer M; Buchholz B
    BMC Nephrol; 2020 Mar; 21(1):104. PubMed ID: 32204691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Management of transplant-associated thrombotic microangiopathy].
    Ikezoe T
    Rinsho Ketsueki; 2018; 59(10):2307-2314. PubMed ID: 30305540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
    Schoettler M; Lehmann L; Li A; Ma C; Duncan C
    Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment.
    Rosenthal J
    J Blood Med; 2016; 7():181-6. PubMed ID: 27621680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.